Shots: Regeneron is presenting results from studies evaluating Libtayo in indications NSCLC (P-I), CSCC(P-I), HCC(P-I), BCC (P-II), R/M Cervical Cancer (P-I), Libtayo + RT+ GM-CSF for R/M HNSCC (P-I) Libtayo is a mAb targeting the immune checkpoint receptor PD-1 and was recently approved by the US FDA to treat locally advanced CSCC or mCSCC In […]Read More
